Skip to main content
Industry News
FDA accepts NDA for Intercept's obeticholic acid
12/2/2019

The FDA accepted the New Drug Application filed by Intercept Pharmaceuticals for obeticholic acid, which is indicated as a treatment for fibrosis as a result of non-alcoholic steatohepatitis. The filing was granted Priority Review status, and a PDUFA action date was set for March 26.

Full Story: